middle.news
How Amplia’s FDA Nod Could Transform Pancreatic Cancer Trials
10:22am on Thursday 20th of November, 2025 AEDT
•
Healthcare
Read Story
How Amplia’s FDA Nod Could Transform Pancreatic Cancer Trials
10:22am on Thursday 20th of November, 2025 AEDT
Key Points
FDA supports two-dose comparison design in Phase 2b trial
Minor protocol changes expected with minimal timeline impact
Full trial protocol submission planned for first half of 2026
Trial combines narmafotinib with gemcitabine and Abraxane
Read Story
middle.
Tap to Read
Tap the card to read the full analysis
about
ATX
OPEN ARTICLE